Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares
(NQ:
QNTM
)
3.570
+0.370 (+11.56%)
Streaming Delayed Price
Updated: 3:30 PM EDT, Sep 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
135,023
Open
3.220
Bid (Size)
3.520 (300)
Ask (Size)
3.580 (100)
Prev. Close
3.200
Today's Range
3.135 - 3.570
52wk Range
2.070 - 21.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND
Today 9:39 EDT
Via
Investor Brand Network
NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research
Today 8:30 EDT
From
NetworkNewsWire
Via
GlobeNewswire
Performance
YTD
-49.1%
-49.1%
1 Month
-6.1%
-6.1%
3 Month
-3.5%
-3.5%
6 Month
+51.3%
+51.3%
1 Year
-79.5%
-79.5%
More News
Read More
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial
September 11, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
September 11, 2026
From
Quantum BioPharma Ltd.
Via
GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via
Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
September 10, 2026
Via
Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial
September 09, 2026
Via
Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
September 10, 2026
From
BioMedWire
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial
September 09, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment
September 09, 2026
From
Quantum BioPharma Ltd.
Via
GlobeNewswire
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via
Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential
August 31, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development
August 27, 2026
Via
Investor Brand Network
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
From
BioMedWire
Via
GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment
August 19, 2026
Via
Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves
August 19, 2026
Via
Investor Brand Network
These stocks are moving in today's pre-market session
↗
August 17, 2026
Via
Chartmill
NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2
August 14, 2026
Via
Investor Brand Network
Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial
August 14, 2026
From
Quantum BioPharma
Via
GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis
August 12, 2026
Via
Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS into Phase 2
August 10, 2026
Via
Investor Brand Network
Frequently Asked Questions
Is Quantum Biopharma Ltd. - Class B Subordinate Voting Shares publicly traded?
Yes, Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is publicly traded.
What exchange does Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trade on?
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is QNTM on the Nasdaq Stock Market
What is the current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is 3.570
When was Quantum Biopharma Ltd. - Class B Subordinate Voting Shares last traded?
The last trade of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares was at 09/14/26 03:30 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
